



HAL
open science

Evaluation of *Clostridium botulinum* A5 neurotoxin actions in vivo and ex vivo at the mouse skeletal neuromuscular junction

Évelyne Benoit, Aurélie Couesnon, Bogdan I Iorga, Michel R. Popoff, Jordi Molgó

► **To cite this version:**

Évelyne Benoit, Aurélie Couesnon, Bogdan I Iorga, Michel R. Popoff, Jordi Molgó. Evaluation of *Clostridium botulinum* A5 neurotoxin actions in vivo and ex vivo at the mouse skeletal neuromuscular junction. RT28 – 28th Meeting of the French Society of Toxinology – Toxins: What’s up, Doc?, Nov 2022, Paris, France. hal-04472746

HAL Id: hal-04472746

<https://hal.science/hal-04472746>

Submitted on 22 Feb 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Evaluation of Clostridium botulinum A5 neurotoxin actions in vivo and ex vivo at the mouse skeletal neuromuscular junction










Evelyne BENOIT¹, Aurélie COUESNON², Bogdan I. IORGA³, Michel R. POPOFF⁴, Jordi MOLGÓ^{1,2*}



¹Université Paris-Saclay, CEA, Institut des Sciences du Vivant Frédéric Joliot, Equipe Mixte de Recherche CNRS/CEA 9004, Département Médicaments et Technologies pour la Santé, Service d'Ingénierie Moléculaire pour la Santé (SIMoS), F-91191 Gif-sur-Yvette, France. ²Institut des Neurosciences Paris-Saclay, UMR 9197 CNRS/Université Paris-Sud, F-91198 Gif-sur-Yvette, France. ³CNRS, Institut de Chimie des Substances Naturelles, UPR 2301, Labex LERMIT, F-91198 Gif-sur-Yvette, France. ⁴Institut Pasteur, Unités des Bactéries Anaérobies et Toxines, Paris, France.

Clostridium botulinum neurotoxins (BoNTs), the most potent toxins known, are the cause of a worldwide life-threatening disease in humans and animals known as botulism. This disease usually manifests as descending symmetrical flaccid paralysis of skeletal muscles together with autonomic dysfunction. BoNTs include a large family of zinc metalloproteases that can be immunologically distinguished by homologous antitoxins into seven primary serotypes, designated A to G. Additionally, for BoNT/A, at least 8 subtypes (/A1-/A8) have been identified from gene sequence analysis. In France, several cases of human botulism due to BoNT/A5, /A6 or /A7 have been reported, though BoNT/A1 and /A2 are the prevalent forms of type-A botulism. The characterization of the C. botulinum strains involved in two cases of BoNT/A5-poisoning revealed that they possess the gene encoding for BoNT/A5 identical to the one previously reported.

In the present study, we produced the BoNT/A5 crude complex (3 x 10⁷ LD₅₀/mg) from the C. botulinum A5 strain 126.07 [1], and studied in vivo and ex vivo, in murine models, the skeletal neuromuscular block caused by BoNT/A5, at different times after a single local toxin injection into the hind-limbs or the head.



CONCLUSIONS: (i) the duration and degree of paralysis depends on the BoNT/A5, and the mouse strain; (ii) DAS assay allowed evaluating the BoNT/A5-induced paralysis, a better information was obtained by measuring the CMAP on the "same mouse" at various times after toxin injection. (iii) Ex vivo studies revealed: (a) the presence of axonal outgrowths (nodal and nerve terminal sprouts), (b) an extension of nicotinic acetylcholine receptor clusters, (c) a reduction in muscle weight and apparent diameter of fibers, and the prolonged atrophy of muscle fibers; (iv) Pre- and postsynaptic remodeling was completely abolished by an immune-purified rabbit polyclonal antibody directed against the BoNT/A1-Hc1

Funded in part by the project ANTIBOTAB of the European Union, and in part by the CNRS and the Pasteur Institute. A.C. was supported by a postdoctoral fellowship from DGA